{'fraction_non_alphanumeric': 0.031141868512110725, 'fraction_numerical': 0.00865051903114187, 'mean_word_length': 5.655172413793103, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Group comparative trial of 2% sodium cromoglycate (Opticrom) with placebo in the treatment of seasonal allergic conjunctivitis

A double‐blind group comparative trial comparing Opticrom with a matching placebo, over a four‐week period, in seasonal allergic conjunctivitis is reported. Overall assessment of treatment benefit made at the end of the trial by the patients and the clinician showed a statistically significant difference in favour of Opticrom. Of the patients on Opticrom, eighteen (90%) said they improved while in the clinicians opinion, seventeen (85%) improved.